Source:http://linkedlifedata.com/resource/pubmed/id/18774334
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2008-9-16
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1388-9842
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
817-8
|
pubmed:dateRevised |
2011-6-8
|
pubmed:meshHeading |
pubmed-meshheading:18774334-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18774334-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:18774334-Heart Failure,
pubmed-meshheading:18774334-Humans,
pubmed-meshheading:18774334-Losartan,
pubmed-meshheading:18774334-Randomized Controlled Trials as Topic,
pubmed-meshheading:18774334-Research Design
|
pubmed:year |
2008
|
pubmed:articleTitle |
All clinical trials are not created equal: The dilemma of HEAAL.
|
pubmed:publicationType |
Editorial
|